International Stem Cell Corporation
ISCOOTCHealthcare● Active
$0.17
+$0.00(+0.00%)
Market Cap$1360746
P/E Ratio—
52W High$0.27
52W Low$0.11
International Stem Cell Corporation (ISCO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ISCO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.10M | $9.09M | $7.79M | $8.18M | $7.18M |
| Cost of Revenue | $4.03M | $3.76M | $3.18M | $3.27M | $2.94M |
| Gross Profit | $5.07M | $5.32M | $4.61M | $4.91M | $4.24M |
| Gross Margin %(computed) | 55.68% | 58.57% | 59.16% | 60.04% | 59.10% |
| Operating Expenses | |||||
| R&D Expenses | $0.68M | $0.66M | $0.51M | $0.49M | $0.69M |
| G&A Expenses | $3.53M | $3.52M | $3.51M | $3.36M | $4.08M |
| Total Operating Expenses | $5.33M | $5.39M | $5.27M | $5.09M | $6.16M |
| Operating Income | ($0.27M) | ($0.07M) | ($0.66M) | ($0.20M) | ($1.92M) |
| Operating Margin %(computed) | -2.93% | -0.75% | -8.51% | -2.40% | -26.77% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.15M | $0.14M | $0.14M | $0.14M | $0.13M |
| Income Before Tax | ($0.42M) | ($0.21M) | ($0.13M) | ($0.33M) | ($0.90M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($0.42M) | ($0.21M) | ($0.13M) | ($0.47M) | ($1.04M) |
| Net Margin %(computed) | -4.59% | -2.30% | -1.68% | -5.70% | -14.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.05 | $-0.03 | $-0.02 | $-0.06 | $-0.13 |
| Wtd Avg Shares | 8.00M | 8.00M | 8.00M | 8.00M | 7.83M |
| EBITDA | ($0.05M) | $0.14M | $0.20M | $0.02M | ($0.22M) |
| EBITDA Margin %(computed) | -0.53% | 1.56% | 2.59% | 0.27% | -3.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more International Stem Cell Corporation data
About International Stem Cell Corporation (ISCO) Income Statement
International Stem Cell Corporation (ISCO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ISCO reported revenue of $0.01B, gross profit of $0.01B (gross margin 55.68%), and net income of ($0.00B) — a net profit margin of -4.59%.
Frequently asked questions
ISCO · 4 questionsInternational Stem Cell Corporation (ISCO) reported revenue of $0.01B for 2025, up 0.2% year-over-year.
ISCO revenueISCO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09